anti-tac(fv)-pe38
mAbexperimentalADC
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 1996 (NCT00002765)
Timeline
Indications
Mechanism of action
- Interleukin-2 receptor alpha chainBINDING AGENT
IL2RA binding agent
Immunotoxin.
- Elongation factor 2INHIBITOR
Elongation factor 2 inhibitor
- Peripheral myelin protein 22INHIBITOR
PMP22 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Pseudomonas exotoxin A
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109367 ↗
Also known as
- anti-tac(fv)-pe38
- anti-tac(fv)-pe38 (lmb-2) immunotoxin
- b3(fv)-pe38kdel
- b3(fv)-pe38kdel recombinant immunotoxin
- lmb-2
- lmb-2
- lmb-2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00924170 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2008 | National Cancer Institute (NCI) |
| NCT00389506 | N/A | Sep 1, 2006 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00321555 | Phase 2 | Apr 27, 2006 | National Cancer Institute (NCI) |
| NCT00295958 | Phase 2 | Dec 1, 2005 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00085150 | Phase 1 | Apr 1, 2004 | National Cancer Institute (NCI) |
| NCT00080535 | Phase 2 | Apr 1, 2004 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00077922 | Phase 2 | Feb 1, 2004 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00002765 | Phase 1 | Apr 1, 1996 | National Cancer Institute (NCI) |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 8 | 6 | 3 | 1996 |
| National Institutes of Health (NIH) | Government | 4 | 2 | 2 | 2004 |
2 organizations
Page 1 / 1